ClinicalTrials.gg
CompletedNCT03890809Updated Aug 26, 2020

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

A Phase 1 interventional study of BMS-986165 in Liver Dysfunction and Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Liver Diseases by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Liver Diseases · Bristol-Myers Squibb.

Started
2019
the only one that year
Phase 1
7 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Liver Diseases by Bristol-Myers Squibb, this one is the only one that started in 2019, is one of 7 in phase 1, and was the 6th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

None of the 11 studies in Liver Diseases by Bristol-Myers Squibb is open now. The open studies under Liver Diseases, anywhere →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Liver Diseases by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.

03

Conditions studied

  • Liver Dysfunction
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • of 18.0 to 38.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
  • Normal renal function at screening as evidenced by an estimated (GFR) > 80 mL/min/1.73 m2 for participants

Exclusion criteria

Exclusion Criteria:

  • abnormal medical history, abnormal findings on physical examination, vital signs, , or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant
  • History or clinical evidence of acute or chronic bacterial infection (eg, pneumonia, septicemia) within 3 months prior to screening
  • Have a history of cancer () with the following exceptions: (1) participants with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) participants with other malignancies who have been successfully treated ≥10 years prior to the screening visit where, in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the screening visit

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Normal liver function

    Single dose

    Drug: BMS-986165

  • Experimental
    Mild liver impairment

    Single dose

    Drug: BMS-986165

  • Experimental
    Moderate liver impairment

    Single dose

    Drug: BMS-986165

  • Experimental
    Severe liver impairment

    Single dose

    Drug: BMS-986165

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Approximately 9 days

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]

    Time frame: Approximately 9 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Approximately 9 days

Secondary outcomes

  1. Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation

    Time frame: Approximately 44 days

  2. Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations

    Time frame: Approximately 44 days

07

Study locations

4 sites
  • Pharmaceutical Research Associates CZ, s.r.o
    Praha 7, 170 00, Czechia
  • Kenezy Gyula Korhaz es Rendelointezet
    Debrecen, 4043, Hungary
  • Clinical Research Unit Hungary
    Miskolc, 3529, Hungary
  • Local Institution
    Bratislava, 831 01, Slovakia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Nov 2019, 9 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 26, 2019
StartActual
Feb 26, 2019
Primary completionActual
Nov 30, 2019
CompletionActual
Nov 30, 2019
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03890809
Responsible party
Sponsor
First posted
Mar 26, 2019
Start date
Feb 26, 2019
Primary completion
Nov 30, 2019
Completion
Nov 30, 2019
Last update
Aug 26, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion